Indium (111in) Dtpa Curium Netherlands B.V

Indium-111 pentetate, the active ingredient in Indium (111in) Dtpa Curium Netherlands B.V, is a radiopharmaceutical presented as a solution for intrathecal injection use. It enables visualization of cerebrospinal fluid pathways for diagnostic imaging in patients with suspected CSF leaks or meningeal pathology. GNH USA supplies Indium (111in) Dtpa Curium Netherlands B.V as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and imaging centres worldwide.

Indium-111 pentetate is employed in diagnostic imaging of the cerebrospinal fluid system.

Cerebrospinal fluid imaging: enables visualization of CSF flow and anatomy for assessment of normal and abnormal pathways. Detection of CSF leaks: highlights sites of leakage by tracking radiotracer distribution within the CSF. Evaluation of spinal cord and meningeal pathology: assists in locating lesions, inflammation or tumors affecting the meninges or spinal cord.

Adverse reactions may occur following intrathecal administration of Indium-111 pentetate.

Common Side Effects: - Headache: mild to moderate discomfort after injection. - Nausea: transient feeling of queasiness. - Back pain: localized at the injection site. - Transient fever: low‑grade temperature rise. - Injection site discomfort: mild pain or irritation. - Mild allergic reaction: rash or itching.

Serious or Rare Side Effects: - Radiation‑induced myelopathy: potential spinal cord injury from high radiation exposure. - Severe allergic reaction (anaphylaxis): rapid onset of breathing difficulty, swelling, or hypotension. - Meningitis or CSF infection: signs of infection such as fever, neck stiffness, or neurological changes. - Severe hypotension: sudden drop in blood pressure. - Radiation‑induced thyroid dysfunction: altered thyroid hormone levels. - Severe neuropathic pain: persistent nerve‑related pain after injection.

Prior to use, clinicians should consider several safety measures.

Pregnancy: use only if potential diagnostic benefit outweighs fetal radiation risk. Breastfeeding: discontinue nursing or consider alternative imaging, as radiation may be transferred to the infant. Renal impairment: evaluate renal function because the chelated complex is partially cleared renally. Allergy to pentetate or related chelators: avoid administration in sensitised individuals. Concurrent radiopharmaceuticals: do not co‑administer to prevent additive radiation exposure. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Indium-111 pentetate may interact with other agents that affect imaging quality or radiation exposure.

Major Interactions (Avoid): - High‑dose iodine contrast agents: can interfere with image interpretation. - Other intrathecal radiopharmaceuticals: additive radiation dose may be harmful. - Myelosuppressive chemotherapy: increased risk of hematologic toxicity.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask mild allergic responses. - Corticosteroids: could alter inflammatory response, affecting imaging results. - Renal‑function‑altering drugs: may modify clearance of the chelated complex.